Source:Cancer Treatment Reviews
Author(s): Rositsa G Koleva-Kolarova, Monika P Oktora, Annelies L Robijn, Marcel JW Greuter, Anna KL Reyners, Erik Buskens, Geertruida H de Bock
This article aimed to assess the clinical effectiveness of non-hormonal targeted therapies (TTs) in terms of increase of median progression-free survival (PFS) and overall survival (OS) in receptor-positive metastatic breast cancer (MBC) patients by performing a systematic review and meta-analysis. We systematically searched relevant randomized controlled trials and extracted data about number of patients on targeted and comparator therapy, receptor status, line of treatment, median PFS and OS, p values, hazard ratios (HRs) and 95% confidence intervals (CI). Inverse variance was used to estimate pooled HRs, chi-square test for heterogeneity and Jadad scale for quality were applied. Thirty eight studies (n=17,192 patients) were eligible for inclusion. TTs added 3.3 months to the median PFS [0.7–9.6; HRs 0.74, 95% CI 0.71–0.77] of receptor-positive MBC patients and prolonged their median OS with 3.5 months [0–4.7; HRs 0.90, 95% CI 0.82–0.98]. The highest increase in median PFS of 3.6 months was found in HER2-/HR+ patients, while the highest increase in median OS of 7.2 months was observed in HER2+/mixed hormone receptor (HR) status patients. First-line TTs were most effective in increasing the median PFS in the HR+/HER2- group with 2.0 months, and in the HER2+/HR-mixed group by adding 4.7 months to the median OS. Second-line TTs were most effective for HER2-/HR+ patients by adding 2.6 months to their PFS, and for HER2+/HR-mixed patients by adding 3.1 months to their median OS. Albeit small, the gain in months of median PFS and median OS was significant. Importantly, the results reported show large variation, and thus routinely applying a personalized approach seems warranted.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2ma1VSS
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου